Cause and consequences of sympathetic hyperactivity in chronic kidney disease

Blood Purification

Volumn 24, Issue 1, 2006, Pages 95-99

  Kotanko, Peter ^a  

^a RENAL RESEARCH INSTITUTE   (United States)

Author keywords

Chronic kidney disease; Moxonidine; Muscle sympathetic nerve activity; Rilmenidine; Sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; EPROSARTAN; LOSARTAN; MOXONIDINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PRAZOSIN; RILMENIDINE;

ADRENERGIC SYSTEM; AUTONOMIC NERVOUS SYSTEM; BRAIN STEM; CARDIOMYOPATHY; CAROTID BODY CHEMORECEPTOR; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG MEGADOSE; GENETIC VARIABILITY; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY NERVE; LOW DRUG DOSE; NEUROGRAPHY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SLEEP APNEA SYNDROME; SYMPATHETIC TONE;

ADRENERGIC ALPHA-AGONISTS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARGININE; BRAIN STEM; HUMANS; HYPERKINESIS; HYPERTENSION, RENAL; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; NITRIC OXIDE SYNTHASE; OXAZOLES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL DIALYSIS; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 29244436868     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089444     Document Type: Review

References (27)

1. Koomans HA, Blankestijn PJ, Joies JA: Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004;15: 524-537.
2. Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004;19:1354-1357.
3. Svetkey LP, Timmons PZ, Emovon O, Anderson NB, Preis L, Chen YT: Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype. Hypertension 1996;27:1210-1215.
4. Kotanko P, Binder A, Tasker J, et al: Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor. Hypertension 1997;30:773-776.
5. Esler M, Willett I, Leonard P, et al: Plasma noradrenaline kinetics in humans. J Auton Nerv Syst 1984;11:125-144.
6. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG: Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979;59:919-957.
7. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043-1065.
8. Gratze G, Fortin J, Holler A, et al: A software package for non-invasive, real-time beat-to-beat monitoring of stroke volume, blood pressure, total peripheral resistance and for assessment of autonomic function. Comput Biol Med 1998;28:121-142.
9. Brecht HM, Ernst W, Koch KM: Plasma noradrenaline levels in regular haemodialysis patients. Proc Eur Dial Transplant Assoc 1976;12:281-290.
10. Converse RL Jr, Jacobsen TN, Toto RD, et al: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.
11. Hausberg M, Kosch M, Harmelink P, et al: Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-1979.
12. Katholi RE, Winternitz SR, Oparil S: Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 1982;69:55-62.
13. Krukoff TL: Central actions of nitric oxide in regulation of autonomic functions. Brain Res Brain Res Rev 1999;30:52-65.
14. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004;15:435-441.
15. Tracey KJ: The inflammatory reflex. Nature 2002;420:853-859.
16. Zoccali C, Mallamaci F, Parlongo S, et al: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105: 1354-1359.
17. Koch M, Thomas B, Tschope W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993;36:1113-1117.
18. Cice G, Ferrara L, D'Andrea A, et al: Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-1444.
19. Agarwal R: Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999;55:1528-1535.
20. Cohn JN, Pfeffer MA, Rouleau J, et al: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659-667.
21. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ: Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004;15:2902-2907.
22. Esler M, Lux A, Hastings J, Socratous F, Lambert G: Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion. J Hypertens 2004;22:A7-A8.
23. Aparicio M, Dratwa M, el Esper N, et al: Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol 1994;74:43A-50A.
24. Ligtenberg G, Blankestijn PJ, Oey PL, et al: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-1328.
25. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003;14:425-430.
26. Zilch O, Vos PF, Oey LP, Cramer MM, Koomans HA, Blankestijn PJ: Daily dialysis reduces peripheral vascular resistance and sympathetic activity (abstract). J Am Soc Nephrol 2001;12.
27. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int Suppl 2001;78:S19-S24.